A61K 2239/47
Brain
Official title: Brain; Nervous system
A61K2239/47 (Brain) appears on 166 US grants and 420 published applications in this corpus.
Search patents in A61K- Granted patents
- 166
- Published applications
- 420
- Assignees
- 183
- Inventors
- 691
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 5 |
| 2003 | 0 | 4 |
| 2004 | 1 | 1 |
| 2005 | 1 | 2 |
| 2006 | 0 | 2 |
| 2007 | 0 | 1 |
| 2008 | 1 | 7 |
| 2009 | 1 | 4 |
| 2010 | 2 | 3 |
| 2011 | 2 | 6 |
| 2012 | 3 | 10 |
| 2013 | 6 | 8 |
| 2014 | 5 | 8 |
| 2015 | 5 | 7 |
| 2016 | 5 | 14 |
| 2017 | 8 | 19 |
| 2018 | 8 | 19 |
| 2019 | 6 | 19 |
| 2020 | 11 | 35 |
| 2021 | 8 | 37 |
| 2022 | 12 | 49 |
| 2023 | 18 | 38 |
| 2024 | 19 | 50 |
| 2025 | 20 | 33 |
| 2026 | 19 | 39 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for inhibiting T cell exhaustion8 Sep 2026US 12,729,245 B2The Board of Trustees of the Leland Stanford Junior University
- Methods and compositions for chimeric antigen receptor targeting cancer cells1 Sep 2026US 12,721,892 B2The University of North Carolina at Chapel Hill
- Cell immunotherapy for the treatment of cancer14 Jul 2026US 12,678,486 B2Board of Regents, The University of Texas System
- NK cell compositions and preparations for immunotherapy and methods for their production16 Jun 2026US 12,655,190 B2Deverra Therapeutics Inc.
- Armed dual CAR-T compositions and methods for cancer immunotherapy2 Jun 2026US 12,643,933 B2Simcere Innovation, Inc.
- Nk cell compositions and preparations for immunotherapy and methods for their production8 Oct 2026US 2026/0308226 A1Deverra Therpaeutics Inc.
- Car-t cells co-expressing cd40l1 Oct 2026US 2026/0294969 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Cell immunotherapy for the treatment of cancer1 Oct 2026US 2026/0295011 A1Board of Regents, The University of Texas System
- Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production27 Aug 2026US 2026/0248914 A1
- Neoantigen immunotherapies20 Aug 2026US 2026/0240970 A1Iogenetics, LLC
Most cited
By later US patents
- Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells121US 8,822,647 B2City of Hope · 2014
- Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor113US 9,394,368 B2Novartis AG · 2016
- Chimeric immunoreceptor useful in treating human gliomas101US 8,324,353 B2City of Hope · 2012
- Cancer immunotherapy using tumor cells combined with mixed lymphocytes81US 6,207,147 B1The Regents of the University of California · 2001
- Chimeric immunoreceptor useful in treating human cancers68US 8,497,118 B2City of Hope · 2013